Fasturtec
·
- Prescription status not stated
- Everything that fits nowhere else, such as contrast media
- Active substance
- Rasburicase
- Made by
- Sanofi Winthrop Industrie
- Source
- Official label
Quoted from the official source. Not yet reviewed by Mediclarum — the leaflet in your pack is authoritative.
What it is for
- Treatment and prophylaxis of acute hyperuricaemia, in order to prevent acute renal failure, in adults, children and adolescents (aged 0 to 17 years) with haematological malignancy with a high tumour burden and at risk of a rapid tumour lysis or shrinkage at initiation of chemotherapy.
From the official label · 2026-09-30 · European Medicines Agency
Same active substance, strength and form in other countries
Matched on active substance, strength and kind of form only. This is not a statement that the products are equivalent or interchangeable: other ingredients, release and approved uses can differ — ask a pharmacist before swapping.
Medicine passport: one printable page to show a pharmacist abroad
United StatesNo exact match for this strength and form
SpainNo exact match for this strength and form
FranceNo exact match for this strength and form
CanadaNo exact match for this strength and form
NetherlandsNo exact match for this strength and form
SwitzerlandNo exact match for this strength and form
Details
| Made by | Sanofi Winthrop Industrie |
|---|---|
| Active substance | Rasburicase |
| Used in | Everything that fits nowhere else, such as contrast media |
| Classification | V03AF07 · Everything that fits nowhere else, such as contrast media |
| Authorised on | 2001-02-23 |
| Last updated by the regulator | 2024-08-12 |
| EMA product number | EMEA/H/C/000331 |
Source: European Medicines Agency — medicine data · 2026-09-30 · not reviewed by a clinician
Source: European Medicines Agency (EMA). Product information as published by EMA. Reuse terms: EMA legal notice (reproduction authorised).